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Abstract
Background: In order to develop novel clinical applications and to gain insights into possible therapeutic
mechanisms, detailed molecular characterization of human bone marrow-derived mesenchymal stromal cells
(hBM-MSCs) is needed. Neural cell adhesion molecule (NCAM, CD56) is a transmembrane glycoprotein modulating
cell–cell and cell–matrix interactions. An additional post-translational modification of NCAM is the α2,8-linked
polysialic acid (polySia). Because of its background, NCAM is often considered a marker of neural lineage
commitment. Generally, hBM-MSCs are considered to be devoid of NCAM expression, but more rigorous
characterization is needed.
Methods: We have studied NCAM and polySia expression in five hBM-MSC lines at mRNA and protein levels. Cell
surface localization was confirmed by immunofluorescence staining and expression frequency in the donor-specific
lines by flow cytometry. For the detection of poorly immunogenic polySia, a fluorochrome-tagged catalytically
defective enzyme was employed.
Results: All five known NCAM isoforms are expressed in these cells at mRNA level and the three main isoforms are
present at protein level. Both polysialyltransferases, generally responsible for NCAM polysialylation, are expressed at
mRNA level, but only very few cells express polySia at the cell surface.
Conclusions: Our results underline the need for a careful control of methods and conditions in the characterization
of MSCs. This study shows that, against the generally held view, clinical-grade hBM-MSCs do express NCAM. In
contrast, although both polysialyltransferase genes are transcribed in these cells, very few express polySia at the cell
surface. NCAM and polySia represent new candidate molecules for influencing MSC interactions.
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Background
Human bone marrow-derived mesenchymal stromal
cells (hBM-MSCs) are attractive candidates for cellular
therapy, regenerative medicine, and tissue engineering.
They are adult progenitor cells that hold potential for
fast clonal expansion, secretion of trophic and immuno-
modulatory factors, and multilineage differentiation. In
addition, they are relatively easy to harvest, isolate, and
culture. However, it is widely acknowledged that follow-
ing in-vitro culture, MSCs undergo replicative senes-
cence and appear to lose their beneficial traits [1].
Furthermore, MSC cultures typically consist of a hetero-
geneous mixture of cells at different stages of commit-
ment and potential [1, 2]. In order to develop novel
clinical applications and to gain more insight into the
possible therapeutic mechanisms, detailed molecular
characterization of hBM-MSCs is needed. This will ul-
timately improve the safety and efficacy of cell therapy.
Neural cell adhesion molecule (NCAM, CD56) is a
calcium-independent binding protein engaged in homophi-
lic cell–cell and heterophilic cell–matrix interactions [3].
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NCAM is transcribed from a single gene, but exists
in multiple isoforms as a result of alternative splicing
[4]. In humans, at least five distinct NCAM isoforms
are known. A modification of NCAM results post-
translationally from the addition of linear polymers of
N-acetylneuraminic acid units, polysialic acid (polySia)
[5, 6]. Being a large negatively charged and highly hy-
drated structure, polySia regulates NCAM activity by
altering its biophysical properties [7]. PolySia has an
important role in maintaining developmental plasticity
and cell migration in tissues by influencing cellular inter-
actions [8]. In addition, it is involved in various medical
conditions such as tissue repair, neurodegenerative dis-
eases, and progression of metastatic cancers [9, 10].
Expression of NCAM and polySia is strong and dy-
namic during embryogenesis, decreases and focuses dur-
ing development, and is limited to just few tissues and
cell types in the adult [11, 12]. Because of its original
discovery site, NCAM is often considered a marker of
neural lineage commitment [13, 14]. However, it is
known that expression of NCAM and polySia is wide-
spread during organogenesis, particularly in undifferenti-
ated mesenchymal cells [15]. Many in-vivo and in-vitro
studies in animal models suggest that NCAM is an im-
portant regulator of cell migration and condensation
during skeletal development [16–18]. Hence, NCAM
and polySia represent promising candidates for influen-
cing MSC interactions.
It is generally held that hBM-MSCs do not express
NCAM [19–25], while, for example, placental and um-
bilical cord blood-derived MSCs are eminently NCAM
positive [21, 24, 25]. Brooke et al. [26] have reported that
hBM-MSCs do express NCAM at the mRNA level, but
protein expression was not investigated. NCAM protein
expression, which may indicate increased chondrogenic
potential, has been reported in a small fraction of pri-
mary bone marrow mononuclear cells (0.5–5.5 %), but
expression diminished over time in culture [27, 28]. In con-
trast, murine BM-MSCs predominantly express NCAM,
which plays a crucial role, for example, in hematopoiesis
[29]. Furthermore, experiments with NCAM knockout
mice have shown reduced multilineage differentiation
potential of BM-MSCs compared with wild-type controls
[30, 31]. Thus, because of the role of NCAM and polySia in
the control of cellular differentiation and interaction, it is
important to reliably determine whether they are expressed
in clinical-grade hBM-MSCs.
In this study, we have investigated the expression sta-
tus of NCAM and polySia in clinical-grade hBM-MSCs
using a variety of methods. We have concentrated par-
ticularly on NCAM expression, because we observed a
striking discrepancy between our findings and previous
reports [19–25]. Furthermore, NCAM is the most stud-
ied molecule of the immunoglobulin superfamily of cell
adhesion molecules (CAMs), but has been largely
neglected in stem cell research despite its role as a de-
velopmental regulator. This study clearly demonstrates
the need for comprehensive analyses and careful control
of methods in the characterization of MSCs. Gene and
protein expression analyses show that these cells do, in
fact, express NCAM. In contrast, although polysialyl-
transferases are transcribed in these cells, very few ex-
press polySia on the cell surface.
Methods
Cells
The culture protocol developed by Laitinen et al. [32] for
clinical-grade MSCs based on platelet lysate was utilized
in this study. Bone marrow was collected from five healthy
volunteer donors (donor 067: female, age 24; donor 068:
female, age 31; donor 069: female, age 30; donor 072:
female, age 21; donor 073: female, age 21). Bone marrow
was aspirated under local anesthesia from the posterior
iliac crest and collected in heparinized tubes after
signed informed consent according to the Declaration
of Helsinki. The protocol was approved by the ethics
committee of the Hospital District of Helsinki and
Uusimaa (Finland). The isolation and characterization
of hBM-MSCs has been described in detail previously
[32]. The isolated cells were cultured in heparinized
(LEO Pharma, Ballerup, Denmark) low-glucose Dulbecco’s
modified Eagle’s medium (DMEM; Gibco, Life Technolo-
gies, Paisley, UK), supplemented with 10 % platelet lysate
(Finnish Red Cross Blood Service, Helsinki, Finland), and
100 U/ml penicillin and 100 μg/ml streptomycin (Gibco)
according to Laitinen et al. [32]. The medium was chan-
ged twice weekly and the cultures were passaged when
subconfluent (80 % confluency) and subcultured at 1000–
1500 cells/cm2. The hBM-MSCs used in this study were
freshly analyzed (i.e., noncryopreserved) at passage 2 or 3.
Human neuroblastoma SK-N-SH cells (ATCC, Manas-
sas, VA, USA) were cultured in high-glucose DMEM
(Sigma, St. Louis, MO, USA), supplemented with 10 %
fetal bovine serum (FBS) (HyClone; Thermo Scientific,
Logan, UT, USA), and 100 U/ml penicillin and 100 μg/ml
streptomycin (Gibco). Inactive endosialidase-GFP fusion
protein developed by Jokilammi et al. [33] and magnetic
GFP-Trap®-M beads (Chromotek, Planegg-Martinsried,
Germany) were employed to fractionate the strongly
polySia-expressing cell population (kSK-N-SH) to be used
as a positive control. First, cells were labeled with inactive
endosialidase-GFP fusion protein in phosphate-buffered
saline (PBS; containing 1.06 mM potassium phosphate
monobasic, 155.2 mM sodium chloride, and 2.97 mM so-
dium phosphate dibasic) for 1 hour on ice. Labeled cells
were then mixed with GFP-Trap®-M beads and separated
magnetically until the bead-associated cells were percep-
tibly gathered to the proximity of the magnet. Supernatant
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was discarded and isolated cells were washed with PBS.
Washing and magnetic separation was repeated 10 times.
Lastly, the isolated cells were plated on a cell culture dish
and cultured accordingly. The NCAM and polySia expres-
sion status was analyzed with flow cytometry; the propor-
tion of NCAM and polySia-expressing cells was 98.3 %.
All cells were cultured under a humidified atmosphere
at 37 °C and with 5 % CO2.
Differentiation of hBM-MSCs
Adipogenic differentiation of hBM-MSCs was performed
as described previously by Laitinen et al. [32]. The cells
were cultured in adipogenic differentiation condition for
1–2 weeks. After differentiation the cells were fixed with
4 % paraformaldehyde in PBS for Sudan III staining.
Osteogenic differentiation of hBM-MSCs was carried
out essentially as described previously by Laitinen et al.
[32]. The cells were cultured in osteogenic medium for
3–4 weeks. After differentiation the cells were fixed with
4 % paraformaldehyde in PBS for von Kossa staining.
Chondrogenic differentiation was performed as de-
scribed previously by Skog et al. [34]. The pellet cultures
were maintained up to 4 weeks, changing the medium
twice a week. After differentiation the cell pellets were
fixed with 10 % formalin, embedded in paraffin, and cut
into 5 μm sections for Safranin O staining.
Qualitative reverse transcription PCR
NCAM isoform-specific sequences were obtained from
NCBI Unigene (http://www.ncbi.nlm.nih.gov/unigene).
Primers were designed using NCBI Primer Blast (http://
www.ncbi.nlm.nih.gov/tools/primer-blast) and optimized
by OligoEvaluator™ (http://www.sigmaaldrich.com/technical-
documents/articles/biology/oligo-evaluator.html) or Tm
Calculator (https://www.thermofisher.com/fi/en/home/
brands/thermo-scientific/molecular-biology/molecular-
biology-learning-center/molecular-biology-resource-library/
thermo-scientific-web-tools/tm-calculator.html) PCR web
tools. All commercial kits were used according to the
manufacturer’s instructions. Total RNA was isolated
using the High Pure RNA Isolation Kit (Roche Diag-
nostics, Mannheim, Germany). Reverse transcription
was performed with High Capacity RNA-to-cDNA Kit
(Applied Biosystems, Foster City, CA, USA) with 1 μg
of total RNA. A control reaction omitting the reverse
transcriptase was prepared for each sample. PCRs
were performed in 20 μl final volume with Phusion
Hot Start II High-Fidelity DNA Polymerase (Thermo
Scientific, Waltham, MA, USA) for all NCAM iso-
forms, polysialyltransferases (ST8SIA2 and ST8SIA4),
and controls, except that OneTaq Hot Start DNA Poly-
merase (New England BioLabs, Ipswich, MA, USA) was
used for isoform NCAM-120.
Human NCAM isoform and polysialyltransferase-
specific PCR primers were used for the amplification
(Table 1). For Phusion Hot Start II High-Fidelity DNA
Polymerase, the reaction mixture was composed of 0.02
U/μl of DNA polymerase, Phusion HF Buffer (with
1.5 mM MgCl2), 0.2 mM dNTPs, 0.5 μM primers, 3 %
DMSO, sterile water (Baxter Healthcare, Zürich,
Switzerland), and 2.0 μl of template. For OneTaq Hot
Start DNA Polymerase, the reaction mixture was
composed of 0.025 U/μl of DNA polymerase, OneTaq
Standard Reaction Buffer (with 1.8 mM MgCl2), 0.2 mM
Table 1 Primers used in the study
Primer UniGene Forward (5′➔3′) Reverse (5′➔3′) Amplicon size
(base pairs)
GAPDH Hs.544577 GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC 225
NCAM-All Hs.503878 GGACTTCTACCCGGAACATCAG CGAGCTTAGGTGCACTGGG
NCAM-140 (Variant 1),
NCAM-125 (Variant 4)
798
NCAM-180 (Variant 2) 828
NCAM-120 (Variant 3) 903
NCAM Variant 5 906
NCAM-180 NM_181351.4 GCTTCGTGGACTCGACCAG GCAGATGTACTCTCCGGCATC 126
NCAM-140 NM_000615.6 CGAAGAAAAGACTCTGGATGG TCATGCTTTGCTCTCGTTCT 1498
NCAM-125/140 NM_001242608.1 / NM_000615.6 CGAAGAAAAGACTCTGGATGG GTTCCCCTTGGACTGGC 755
NCAM-125 NM_001242608.1 CAGCCAGTCCAAGGGG TGTAGGATGCAGAATTGCCTC 346
NCAM120/125 NM_001076682.3 / NM_001242608.1 GAGTATGAGGTCTACGTGGTGGC GCAGAGAAAAGCAATGAGACAAAG 152
NCAM-120 NM_001076682.3 TCTGCTAGCTCGTCTACCCC CCAAAGGGGGCACTGATCTT 541
NCAM Variant 5 NM_001242607.1 GCTTCGTGGACTCGACCAG GCAGATGTACTCTCCGGCATC 204
ST8SIA2 Hs.302341 GGGCAACTCGGGGGTCTTGC AAGGCCCGCTGGATGACCGA 162
ST8SIA4 Hs.308628 ACAGGCGCCGGACACTAAACA TGCAGCAAACTCCACCACAGGA 200
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dNTPs, 0.2 μM primers, 1.5 M betaine (Sigma), sterile
water (Baxter Healthcare), and 2 μl of template. Amplifi-
cation was performed for 35 cycles. The PCR products
were analyzed by agarose gel electrophoresis. Glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) was used as
the reference gene.
Western blot
Whole-cell extracts were prepared by lysing the cells in
radioimmunoprecipitation assay (RIPA) buffer pH 6.8
containing 50 mM Trizma® base, 150 mM sodium chlor-
ide, 0.5 % sodium deoxycholate (all from Sigma), and
1 % Triton X-100 (Roche Life Sciences, Indianapolis, IN,
USA), supplemented with EDTA-free protease inhibitor
cocktail (Thermo Scientific, Rockford, IL, USA). For re-
moval of polySia, 10 μg/ml of active endosialidase-GFP
fusion protein [35] was added and the samples were
incubated at 37 °C for 45 minutes. Samples were
mixed with Laemmli sample buffer, loaded, and run
on 4–20 % Mini-PROTEAN® TGX™ Precast gradient
gel (Bio-Rad Laboratories, Hercules, CA, USA) or
7 % SDS-polyacrylamide gel. Proteins were electro-
transferred from the gels to nitrocellulose membranes (GE
Healthcare, Little Chalfont, UK) overnight at 4 °C. The
membrane was blocked with 3 % skimmed milk powder
in PBS with 0.1 % Tween-20 for 3 hours at 4 °C.
For NCAM detection, the membrane was incubated
with a primary antibody mixture containing 0.33 μg/ml
rabbit polyclonal anti-human NCAM antibody (AB5032;
Millipore, Temecula, CA, USA) and 0.067 μg/ml mouse
monoclonal anti-human NCAM antibody (123C3; Santa
Cruz, Dallas, Texas, USA) in blocking solution overnight
at 4 °C. Because anti-NCAM antibodies may detect dif-
ferent isoforms with varying affinity in western blot, two
primary antibodies were used simultaneously to ensure
accurate detection of all isoforms [36]. After three
washes, the membrane was incubated with a secondary
antibody mixture containing HRP-conjugated anti-rabbit
secondary antibody 1:3000 and anti-mouse secondary
antibody 1:3000 (both from Cell Signaling, Danvers,
MA, USA) in blocking solution for 2 hours at room
temperature. The immunoblots were developed with
SuperSignal® West Pico Chemiluminescent Substrate
(Thermo Scientific). Secondary antibody control con-
firmed the specificity of the labeling, and α-Tubulin (B-
51-2; Sigma) served as a loading control.
Flow cytometry
Cells were double labeled with 10 μg/ml of rabbit poly-
clonal anti-human NCAM antibody (AB5032; Millipore)
followed by AlexaFluor 647-labeled goat anti-rabbit sec-
ondary antibody (Molecular Probes, Invitrogen, Eugene,
OR, USA) and inactive endosialidase-GFP fusion protein
[33] in PBS. Parallel samples were labeled with
AlexaFluor 647 mouse anti-human alkaline phosphatase
antibody (B4-78; BD Biosciences, San Jose, CA, USA)
and FITC mouse anti-human CD44 antibody (BD
Biosciences) according to the manufacturer’s instruc-
tions. Appropriate fluorescence minus one (FMO) con-
trols were used for analysis. The cells were analyzed
with FACS LSR II flow cytometer and FACSDiva 5.0.3
software (BD Biosciences). Cell debris and dead cells
were excluded from the analysis based on physical pa-
rameters and propidium iodide (PI) fluorescence probing
for cell viability (proportion of positive cells 1.2–7.0 %,
data not shown).
Immunocytochemistry
For immunocytochemical staining, cells were grown on
glass coverslips and fixed with 4 % paraformaldehyde in
PBS. Nonspecific binding was blocked with 1.5 % normal
horse serum (Vector Laboratories, Burlingame, CA, USA)
in PBS. Cells were labeled with 10 μg/ml of rabbit poly-
clonal anti-human NCAM antibody (AB5032; Millipore)
followed by AlexaFluor 647 conjugated goat anti-rabbit
secondary antibody (Molecular Probes) and inactive
endosialidase-GFP fusion protein [33], all in PBS. Cover
slips were mounted with ProLong Mounting Medium
with DAPI (Molecular Probes). The staining was visual-
ized with an Olympus BX50F-3 microscope and imaged
by a PCO CCD Imaging SensiCam color camera and
Image-Pro Plus 4.0 software.
Results
Multilineage differentiation of hBM-MSCs
The multilineage differentiation assay was performed to
verify the differentiation capacity of hBM-MSCs accord-
ing to the International Society for Cellular Therapy
(ISCT) minimal criteria for MSCs [37]. All hBM-MSC
lines displayed typical MSC differentiation capacity along
the adipogenic, osteogenic, and chondrogenic lineages
(Fig. 1).
Expression of NCAM and polysialyltransferase mRNA in
hBM-MSCs
To gain an overview of NCAM mRNA expression, quali-
tative reverse transcription PCR analysis was performed
with isoform-specific primer pairs (Fig. 2a). The reverse
transcription PCR analysis revealed distinct expression
of all NCAM isoform mRNAs in the three analyzed
hBM-MSC lines (Fig. 2b).
NCAM polysialylation is catalyzed by two Golgi resident
enzymes, polysialyltransferases ST8SIA2 and ST8SIA4
(Fig. 3a). Transcription of polysialyltransferases was
analyzed to confirm the prospect of NCAM polysia-
lylation. The analysis shows unambiguously that both
transferase mRNAs are transcribed in the three
hBM-MSC lines analyzed (Fig. 3b).
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Surface expression of NCAM and polySia in hBM-MSCs
Using commercially available polyclonal human-specific
NCAM antibody, we detected cell surface NCAM ex-
pression on hBM-MSCs in flow cytometry (Fig. 4a), indi-
cating that NCAM mRNA is translated into protein. All
five hBM-MSC lines included in this study expressed
NCAM on the cell surface. However, its occurrence was
heterogeneous, because not all cells in the populations
expressed NCAM at detectable levels. Differences be-
tween donor-specific hBM-MSC lines were also ob-
served, the proportion of positive cells ranging from
23.6 ± 0.8 % to 88.5 ± 7.4 % (Fig. 4b). Concurrent polySia
detection was performed with inactive endosialidase-
GFP fusion protein that binds to polySia. Surprisingly,
only very few hBM-MSCs expressed polySia (Fig. 4a),
the proportion of positive cells ranging from 0.5 ± 0.2 %
to 4.4 % (Fig. 4b). All polySia-expressing cells were
simultaneously labeled positively for NCAM, the main
carrier of polySia.
For comparison, cell surface expression of CD44 and
tissue nonspecific alkaline phosphatase (TNAP) was also
analyzed from hBM-MSC lines. Flow cytometry data in-
dicate that CD44, a common MSC marker, is fully
expressed in all of the lines (>99 %, Fig. 4b). On the
other hand, expression of the early osteogenic marker
TNAP was more heterogeneous, ranging from 55.3 % to
92.8 ± 3.7 % (Fig. 4b). No correlation was found between
NCAM and TNAP expression.
Expression of NCAM isoforms in hBM-MSCs
NCAM protein expression was further confirmed by
western blot analysis (Fig. 5). Bands of approximately
180, 140, and 120 kDa in size were detected in all hBM-
MSC lines analyzed, indicating the presence of the three
main isoforms of NCAM. At the protein level, hBM-
MSCs seem to express predominantly NCAM-180 and
other isoforms to a lesser extent. However, distinction
between NCAM-125 and NCAM-120 was not possible
because the bands overlap. Some variation in the expres-
sion of different isoforms was observed between the
hBM-MSC lines, MSC 069 expressing different isoforms
in more equal manner compared with other hBM-MSC
lines. Because polySia may affect NCAM mobility in gel
electrophoresis, endosialidase [35] was used to treat a
set of parallel samples. In agreement with high polySia
expression on kSK-N-SH cells (Fig. 5), endosialidase
treatment revealed the presence of NCAM in these
cells. In contrast, endosialidase treatment did not un-
cover additional NCAM in hBM-MSCs. Altogether,
the western blot results demonstrate that hBM-MSCs
express various NCAM isoforms also at the protein
level.
Fig. 1 Multilineage differentiation of hBM-MSCs. Representative light microscopic photographs of control and differentiated hBM-MSCs. Adipogenic
differentiation was confirmed by Sudan III staining, osteogenic differentiation by von Kossa staining, and chondrogenic differentiation by Safranin O
staining. All hBM-MSC lines displayed typical differentiation capacity. Adipogenic and chondrogenic differentiation images were taken at 10× lens
objective magnification, osteogenic differentiation images at 4× lens objective magnification. MSC mesenchymal stromal cell
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Cellular localization of NCAM and polySia
To determine the subcellular localization of NCAM and
polySia, immunocytochemical detection was utilized.
NCAM appears to be expressed in a clustered manner
over the cell surface in hBM-MSCs (Fig. 6). In contrast,
NCAM expression was even and smooth on the refer-
ence neuroblastoma cell line kSK-N-SH. NCAM expres-
sion in kSK-N-SH seems to be more intense around
cell–cell contact sites, whereas this was not the case for
hBM-MSCs.
Compared with NCAM, very little polySia expression
was detected in hBM-MSCs (Fig. 7). Grainy polySia ex-
pression was detected mainly on cellular extensions.
This was very different from the polySia expression in
kSK-N-SH cells, where polySia is distributed smoothly
all over the cell surface. In kSK-N-SH cells, polySia ex-
pression, together with NCAM, appears to be more
intense in cell–cell contacts; however, in hBM-MSCs
such condensation was not detected. Altogether, the im-
munocytochemistry results confirm that NCAM protein
is expressed on the cell surface.
Discussion
Previous studies have shown that NCAM is a modulator
of various cellular functions such as cell–cell and cell–
matrix interactions, neuronal migration, neurite out-
growth, and synapse formation [3, 38, 39]. Furthermore,
it is an important regulator of cell migration and con-
densation during skeletal development [16–18]. It is
noteworthy that NCAM is not merely an adhesion mol-
ecule, but initiates the formation of intracellular
membrane-proximal signaling complexes, thereby acti-
vating a complex network of signal transduction [40]. In
addition, polySia affects cellular functions such as
Fig. 2 NCAM transcription in hBM-MSCs. NCAM is transcribed from a single gene, located in chromosome 11q23.1, consisting of at least 25 exons.
As a result of alternative splicing, the protein exists in multiple isoforms. Qualitative reverse transcription PCR analysis was performed to gain an
overview of NCAM mRNA expression. a Five distinct isoforms are known and can be detected with a common primer pair (NCAM-All) or isoform-
specific primers as indicated. b All known NCAM isoforms are expressed in hBM-MSCs at the mRNA level. NCAM-expressing neuroblastoma cell
line kSK-N-SH served as a control. bp base pairs, GAPDH glyceraldehyde 3-phosphate dehydrogenase, MSC mesenchymal stromal cell, NCAM
neural cell adhesion molecule, RT reverse transcriptase
Skog et al. Stem Cell Research & Therapy  (2016) 7:113 Page 6 of 12
migration, cytokine response, cell contact-dependent dif-
ferentiation, and immune response modulation [41–44].
To date, definite information about NCAM and polySia
expression in hBM-MSCs has been lacking. Because of
the intrinsic heterogeneity of the MSC populations, donor
variation, and diversity in culture conditions and analysis
methods, biomolecular and cytometric characterization of
MSCs from different laboratories is not easy to compare
[2]. Furthermore, transcriptomic profiling has become a
popular method for characterizing MSCs, but protein and
mRNA expression levels do not always correlate. Analysis
at the protein level is therefore needed before conclusions
about the MSC phenotype can be drawn.
To gain more insight into the characteristics of xeno-
free hBM-MSCs, we have utilized an established clinical-
grade culture protocol based on human platelet lysate
[32]. Platelet lysate has been approved as a safe and ef-
fective supplement for MSC cultivation in vitro [45].
Conventional cell culture methods involve many animal-
derived components; however, they are not desirable for
clinical-grade cell production because of the increased
risk of cross-contamination and host immune reactions
[46]. In addition, xenogeneic additives, like bovine sera,
may negatively alter the self-renewal and stemness of
hBM-MSCs [47]. Because MSCs are very rare in the
bone marrow, isolation and in-vitro expansion of the
cells is usually required prior to their use. We analyzed
noncryopreserved cells at passage 2 or 3, which is the
time point of choice for most MSC applications because
it offers the minimum required number of cells that still
hold functional potency [48, 49]. NCAM and polySia ex-
pression is possibly altered during in-vitro culture. How-
ever, analysis of the properties of these cells directly
from the bone marrow would be challenging because re-
liable markers for their identification are lacking. Culture
of MSCs for at least two passages is commonly used to
attain population purity [48].
Our findings regarding NCAM expression in hBM-
MSCs differ from those reported previously [19–25],
and show—in contrast to the generally held view—that
the cells in fact do express NCAM. Furthermore, we
conducted a more detailed analysis regarding NCAM
gene and protein expression. Our data show that all five
known NCAM isoforms are transcribed in hBM-MSCs.
In particular, the main isoforms are detected at the pro-
tein level. NCAM protein is expressed throughout the
cell surface in a clustered manner. However, flow cyto-
metric analysis revealed quite broad donor-specific vari-
ation in expression levels between the hBM-MSC lines.
This is not unexpected even in our relatively homoge-
neous donor population (healthy females, age 21–31
years), because it has been reported previously that
hBM-MSC cultures are heterogeneous mixtures of cells,
the properties and potency of which vary greatly be-
tween individual donors independent of age or gender
[50–52]. In this study, the donor population was not se-
lected based on any specific characteristic, but samples
were obtained from the volunteer donors in the order
they came in based on the national guidelines for bone
marrow donation eligibility. In Finland, as in most other
western countries, the majority of bone marrow donors
are female [53]. In general, gender has little effect on
hBM-MSC features [50, 54, 55].
There are many possible reasons for the conflicting re-
ports about NCAM expression. MSCs are cultured under
various conditions (e.g., FBS, human serum, platelet lysate,
Fig. 3 Polysialyltransferase transcription in hBM-MSCs. NCAM polysialylation is catalyzed by two Golgi resident enzymes, polysialyltransferases
ST8SIA2 and ST8SIA4. Qualitative reverse transcription PCR analysis was performed to indicate the presence of polysialyltransferases. a ST8SIA2
gene is located in chromosome 15q26 and consists of six exons, whereas ST8SIA4 gene is located in chromosome 5q21 and is comprised of five
exons. b Both polysialyltransferases are transcribed in hBM-MSCs. The polySia-expressing neuroblastoma cell line kSK-N-SH was used as a control.
bp base pairs, GAPDH glyceraldehyde 3-phosphate dehydrogenase, MSC mesenchymal stromal cell, RT reverse transcriptase
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or serum free) and diverse procedures are employed in
their management. Donor-dependent variation may also
occur. Expression patterns may be regulated temporally
and the cells may be in different stages and passages at
the time of analysis, or have undergone replicative senes-
cence. Also, the cellular phenotype may alter between
fresh and cryopreserved cells. Technical variation may
also be responsible; for example, the variable sensitivity
and isoform specificity of anti-NCAM antibodies may give
rise to misleadingly low or lacking protein expression. Fur-
thermore, the expression of NCAM mRNA transcripts
does not necessarily correlate with the expression of pro-
tein on the cell surface.
For comparison, the hBM-MSC lines were also ana-
lyzed by flow cytometry for the surface expression of
CD44 and TNAP. CD44, a receptor for hyaluronic acid
and a common MSC marker, is involved in the contact
between stem cells and the niche for stemness mainten-
ance, as well as MSC homing [56, 57]. All five hBM-
MSC lines expressed high levels of CD44 (>99 %), as ex-
pected. TNAP is an early osteogenic marker that is
expressed in a stage-specific manner during skeletal de-
velopment [58]. Furthermore, TNAP deficiency causes
bone hypomineralization, abnormalities in brain devel-
opment, cortical malformations, as well as epileptic sei-
zures [59]. Thus, TNAP and NCAM are developmentally
involved in many of the same processes. However, no cor-
relation between TNAP and NCAM expression was ob-
served in the hBM-MSC lines. Also, it has been reported
previously that TNAP expression may vary greatly be-
tween individual donors [50, 60] and our results further
support this finding.
Fig. 4 Flow cytometric analysis of marker expression in hBM-MSCs. Flow cytometric analyses were performed to determine the prevalence of
marker expression in hBM-MSC lines. a Plots of NCAM antibody and endosialidase-GFP fusion protein-labeled cells shown in comparison with
plots of secondary antibody controls. NCAM was detected in all hBM-MSC lines, but the proportion of positive cells varied. In contrast, the
proportion of polySia positive cells was very low. The NCAM and polySia-expressing cell line kSK-N-SH served as a control. b For comparison,
hBM-MSC lines were analyzed for the expression of CD44, a common MSC marker, and tissue nonspecific alkaline phosphatase (TNAP), an early
osteogenic marker. Standard deviation is indicated. No correlation between marker expressions was detected. MSC mesenchymal stromal cell,
NCAM neural cell adhesion molecule, polySia polysialic acid
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To our knowledge, polySia expression in hBM-MSCs
has not been reported previously. Our results show that
both polysialyltransferases, ST8SIA2 and ST8SIA4, cata-
lyzing polySia synthesis are transcribed in these cells.
However, very few cells express polySia on the cell sur-
face. On closer examination it was perceived that polySia
is expressed mostly on the cell extensions, in accordance
with its natural role as a promoter of cell projection out-
growth and targeting [61]. Difference in polysialyltransfer-
ase expression and polysialylation levels is an interesting
finding, because traditionally it is thought that expression
of polySia correlates with transcription of polysialyltrans-
ferases [62, 63]. However, it has been previously shown
that other, calcium-dependent, nontranscriptional regula-
tory pathways also exist [64]. Such nontranscriptional
regulation may be due to the spatiotemporal nature of
polySia, requiring specific cues for prompt and selective
expression on the cell surface [65, 66].
Different cell types express different glycan signatures,
a property which has also been utilized to identify and
purify stem cells [67]. For example, the glycolipids
SSEA-3 and SSEA-4 are amongst the most commonly
used markers to identify embryonic stem cells; however,
they are not necessary for the maintenance of pluripo-
tency [68]. It is well known that expression of polysialy-
lated NCAM decreases during postnatal development
and mostly unpolysialylated NCAM is expressed in adult
tissues, where it regulates cell interactions independent
of polySia [69, 70]. In addition, a recent study shows that
polysialylation is regulating human pluripotent stem cell
differentiation into the three germ layers [63]. In the
mesoderm, ST8SIA4 is the principle polysialyltransferase
Fig. 5 NCAM protein expression in hBM-MSCs. NCAM is expressed as transmembrane (NCAM-180 and NCAM-140), membrane-anchored (NCAM-
125 and NCAM-120), or secreted (any isoform) protein. Western blotting was performed to identify which NCAM isoforms are expressed at the
protein level in hBM-MSCs. In gel electrophoresis, polySia may affect the mobility of NCAM. Parallel samples were thus treated with endosialidase
(+Endo) to remove polySia. NCAM was detected with a mixture of two primary antibodies. All of the main NCAM isoforms—NCAM-180, NCAM-
140, and NCAM-120—were detected from the whole cell lysates of hBM-MSCs. The NCAM-120 and NCAM-125 isoforms could not be distinguished
from one another. The NCAM-expressing neuroblastoma cell line kSK-N-SH served as a positive control. Secondary antibody control confirmed the
specificity of the labeling and α-Tubulin served as a loading control. MSC mesenchymal stromal cell, NCAM neural cell adhesion molecule
Fig. 6 NCAM localization in hBM-MSCs. Immunofluorescence staining was performed to study NCAM localization. Exemplified fluorescence
microscopic photographs of antibody-labeled nonpermeabilized cells. On hBM-MSCs, NCAM is expressed in a clustered manner around the cell
surface. In contrast, NCAM expression on kSK-N-SH cells appears to be even and smooth, and concentrating towards cell–cell contact sites.
Secondary antibody control confirmed the specificity of the staining. Scale bar = 25 μm. DAPI 4′,6-diamidino-2-phenylindole, MSC mesenchymal
stromal cell, NCAM neural cell adhesion molecule
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under normal conditions, but this switches to ST8SIA2
when ST8SIA4 activity is eliminated [63]. The observed
expression pattern of polysialyltransferases and restricted
polysialylation may thus indicate that hBM-MSCs are dif-
ferent from their prenatal pluripotent counterparts. How-
ever, our differentiation results evidently demonstrate that
these cells still possess multilineage differentiation cap-
acity. Furthermore, the uncovered polySia and NCAM ex-
pression may provide novel targets to modify MSC
function [71].
Conclusions
Despite some promising clinical results related to refrac-
tory graft-versus-host disease, the biological properties
of MSCs remain largely unknown and clinical MSC ap-
plications are lacking good markers, which reflect the
clinical efficacy of the cells. Generally, NCAM expres-
sion is considered to be absent from hBM-MSCs, but
the results of our gene and protein expression analysis
show that clinical-grade hBM-MSCs do, in fact, express
NCAM as well as polySia. Hence, these results underline
the need for comprehensive analyses and careful control
of methods in the characterization of MSCs. NCAM and
polySia represent promising new candidates to influence
MSC interactions. However, their functional and clinical
significance needs to be explored in further studies.
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